Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Integrated Traditional Chinese and Western Clinical Medicine, Second Clinical School, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
J Ethnopharmacol. 2024 Mar 1;321:117432. doi: 10.1016/j.jep.2023.117432. Epub 2023 Nov 20.
It has been widely reported that various anti-rheumatic traditional Chinese medicines (TCMs) ameliorate rheumatoid arthritis (RA) and osteoarthritis (OA) through regulating the abnormal production, assembly, and activation of the NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) inflammasome. These TCMs include monomers isolated from Chinese herbs, extracts of Chinese herbs, and Chinese medical formulae with a lengthy application history.
This review aimed to summarize and analyze the published articles about the NLRP3 inflammasome and its role in the pathogenesis of RA and OA. We also reviewed existing knowledge on the therapeutic mechanism of TCMs in RA and OA via the regulation of the NLRP3 inflammasome.
We searched for relevant articles with the keywords "NLRP3 inflammasome", "traditional Chinese medicine," "Chinese herbal drugs," "rheumatoid arthritis," and "osteoarthritis." The information retrieval was conducted in medical Chinese and English databases from the date of construction to April 19, 2023, including PubMed, MEDLINE, Web of Science, Scopus, Ovid, China National Knowledge Infrastructure (CNKI), Chinese Biomedicine Literature Database (CBM), Chinese Science and Technology Periodicals Database (VIP), and China Online Journals (COJ).
According to retrieval results, 35 TCMs have been demonstrated to relieve RA by targeting the NLRP3 inflammasome, including six traditional Chinese prescriptions, seven extracts of Chinese herbs, and 22 monomers extracted from traditional Chinese herbs and formulae. Additionally, 23 TCMs have shown anti-OA effects with abilities to modulate the NLRP3 inflammasome, including five traditional Chinese prescriptions, one extract of Chinese herbs, and 17 monomers from Chinese herbs.
We summarized mechanism research about the pivotal roles of the NLRP3 inflammasome in the pathogenesis of RA and OA. Moreover, a review of TCMs with targets of the NLRP3 inflammasome in RA and OA treatment was also conducted. Our work is conducive to a better application of TCMs in complementary and alternative therapies in RA and OA.
已有广泛报道称,各种抗风湿的中药通过调节 NOD 样受体热蛋白结构域相关蛋白 3(NLRP3)炎性小体的异常产生、组装和激活,来改善类风湿关节炎(RA)和骨关节炎(OA)。这些中药包括从草药中分离出的单体、草药提取物以及具有悠久应用历史的中药方剂。
本综述旨在总结和分析关于 NLRP3 炎性小体及其在 RA 和 OA 发病机制中的作用的已发表文章。我们还回顾了中药通过调节 NLRP3 炎性小体治疗 RA 和 OA 的现有知识。
我们使用关键词“NLRP3 炎性小体”“中药”“中草药”“类风湿关节炎”和“骨关节炎”进行了相关文章的检索。信息检索于 2023 年 4 月 19 日从数据库建立日期开始,在包括 PubMed、MEDLINE、Web of Science、Scopus、Ovid、中国知网(CNKI)、中国生物医学文献数据库(CBM)、中文科技期刊数据库(VIP)和中国期刊全文数据库(COJ)在内的医学中文和英文数据库中进行。
根据检索结果,已有 35 种中药被证明通过靶向 NLRP3 炎性小体来缓解 RA,包括 6 种传统方剂、7 种草药提取物和 22 种从草药和方剂中提取的单体。此外,已有 23 种中药通过调节 NLRP3 炎性小体显示出抗 OA 作用,包括 5 种传统方剂、1 种草药提取物和 17 种草药单体。
我们总结了 NLRP3 炎性小体在 RA 和 OA 发病机制中的关键作用的机制研究。此外,还对 NLRP3 炎性小体在 RA 和 OA 治疗中的中药靶点进行了综述。我们的工作有助于更好地将中药应用于 RA 和 OA 的补充和替代疗法。